Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardiff Oncology (CRDF) Debt to Equity (2016 - 2020)

Cardiff Oncology's Debt to Equity history spans 7 years, with the latest figure at $0.01 for Q2 2020.

  • For Q2 2020, Debt to Equity changed N/A year-over-year to $0.01; the TTM value through Jun 2020 reached $0.01, changed N/A, while the annual FY2017 figure was $0.2, 75.53% down from the prior year.
  • Debt to Equity for Q2 2020 was $0.01 at Cardiff Oncology, down from $0.25 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.55 in Q1 2017 and bottomed at $0.01 in Q2 2020.
  • The 4-year median for Debt to Equity is $0.43 (2016), against an average of $0.52.
  • The largest annual shift saw Debt to Equity skyrocketed 293.69% in 2017 before it tumbled 83.82% in 2018.
  • A 4-year view of Debt to Equity shows it stood at $0.84 in 2016, then plummeted by 75.53% to $0.2 in 2017, then increased by 22.7% to $0.25 in 2018, then plummeted by 96.17% to $0.01 in 2020.
  • Per Business Quant, the three most recent readings for CRDF's Debt to Equity are $0.01 (Q2 2020), $0.25 (Q1 2018), and $0.2 (Q4 2017).